Could a common diabetes drug ease chest pain in women with hidden heart disease?
NCT ID NCT06600178
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This early-stage trial tests whether Brezavvy, a diabetes drug, can improve blood flow in the tiny vessels of the heart and reduce chest pain in women who have angina but no blocked arteries. 150 women will take either the drug or a placebo for 12 weeks and undergo heart scans and questionnaires. The goal is to see if this treatment can help a condition that often goes undiagnosed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGINA PATIENTS WITH NON-OBSTRUCTIVE CORONARY ARTERY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UVA Health
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Brezavvy (a type of diabetes drug called an SGLT2 inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for women with chest pain caused by tiny heart vessel problems, not blocked arteries.
What could go wrong
This is an early Phase 1 trial with only 150 women, so results are preliminary. The drug may not improve symptoms or could cause side effects like dehydration or urinary infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.